Chlamydia trachomatis and Neisseria gonorrhoeae prevalence at final visit
| DMPA-IM group | Copper IUD group | LNG implant group | DMPA-IM vs copper IUD | DMPA-IM vs LNG implant | Copper IUD vs LNG implant | |||||||
| Events/ women | PP (95% CI) | Events/ women | PP (95% CI) | Events/ women | PP (95% CI) | PR (95% CI) | P value | PR (95% CI) | P value | PR (95% CI) | P value | |
| Chlamydia trachomatis | ||||||||||||
| As randomised† | 327/2361 | 13.85 (12.52 to 15.32) | 378/2456 | 15.39 (14.03 to 16.89) | 412/2452 | 16.80 (15.39 to 18.35) | 0.9 (0.79 to 1.04) | 0.144 | 0.83 (0.72 to 0.95) | 0.005 | 0.92 (0.81 to 1.04) | 0.178 |
| Continuous use‡ | 221/1686 | 13.11 (11.59 to 14.82) | 309/1995 | 15.49 (13.98 to 17.16) | 377/2139 | 17.63 (16.08 to 19.32) | 0.86 (0.74 to 1.01) | 0.062 | 0.77 (0.66 to 0.89) | 0.001 | 0.89 (0.78 to 1.02) | 0.093 |
| Neisseria gonorrhoeae | ||||||||||||
| As randomised† | 91/2361 | 3.85 (3.15 to 4.71) | 141/2456 | 5.74 (4.89 to 6.74) | 120/2451 | 4.90 (4.11 to 5.83) | 0.67 (0.52 to 0.87) | 0.002 | 0.79 (0.61 to 1.03) | 0.085 | 1.18 (0.93 to 1.49) | 0.175 |
| Continuous use‡ | 64/1686 | 3.80 (2.99 to 4.83) | 125/ 1995 | 6.27 (5.29 to 7.42) | 110/2138 | 5.14 (4.29 to 6.17) | 0.67 (0.49 to 0.90) | 0.007 | 0.75 (0.56 to 1.02) | 0.064 | 1.13 (0.87 to 1.46) | 0.318 |
*P value is for whether PR differs by subgroup. Subgroup-specific PRs are provided with 95% CIs.
†Adjusted for site only.
‡C. trachomatis analysis: adjusted for age group and baseline C. trachomatis status; N. gonorrhoeae analysis: adjusted for final visit HIV status and total number of pelvic examinations during the study. C. trachomatis analysis: adjusted for age group and baseline C. trachomatis status; N. gonorrhoeae analysis: adjusted for final visit HIV status and total number of pelvic exams during the study.
DMPA-IM, intramuscular depot medroxyprogesterone acetate; IUD, intrauterine device; LNG, levonorgestrel; PP, point prevalence; PR, prevalence ratio.;